Oncternal Therapeutics (ONCT) said late Thursday it entered into a collaboration with AbbVie's (ABBV) Pharmacyclics unit that includes supply of ibrutinib...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Oncternal Therapeutics (ONCT) said Wednesday that it has deprioritized the development of ONCT-216 to reallocate resources to zilovertamab, which is...
...
| Address | 12230 El Camino Real San Diego, California 92130 |
| Phone | +1.858.434.1113 |
| Number of Employees | 21 |
| Recent SEC Filing | 08/09/2022 8-K |
| President, Chief Executive Officer & Director | James B. Breitmeyer |
| Chief Financial Officer, Secretary & Treasurer | Richard Glenn Vincent |
| Chief Scientific Officer | Gunnar F. Kaufmann |
| Chief Technology Officer | Rajesh Krishnan |
| Price Open | $1.17 |
| Previous Close | $1.16 |
| 52 Week Range | $0.69 - 4.63 |
| Market Capitalization | $63.9 M |
| Shares Outstanding | 53.2 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/03/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.79 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -1,086.66% |
| Return on Equity | -46.73% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
